Biotech Values

[mcbio]

MDGL. ...mcbio ...At end of Q3 they had $62 m in cash , marketable securities etc and had operating expenses of only $8.6m in the last Qt. They are running 105 and 125 patient trials that are fully enrolled and will read out late Jan 2018 and late April 2018 .

I get MDGL is already in decent financial shape. Still, in the face of a sharp move up and key binary events still to come, it's not unusual at all to see a biotech even in good financial shape to take advantage of a sharp rise in price in such a scenario.

I'm waiting until the new year to take profits in a name to delay my tax bill but MDGL is on my short list of names to consider early next year.